CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Apr. 30, 2013	Apr. 30, 2012
Cash flows from operating activities
Net income	$ 29,026	$ 21,688
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	5,380	5,129
Amortization	7,438	6,846
Stock-based compensation expense	2,806	3,019
Amortization of debt issuance costs	262	282
Loss on disposal of fixed assets	124	94
Impairment of convertible notes receivable		605
Deferred income taxes	(1,890)	(1,187)
Excess tax benefits from stock-based compensation	(1,986)	(1,315)
Changes in assets and liabilities, net of assets acquired and liabilities assumed:
Accounts receivable	(2,136)	4,012
Inventories	(4,313)	(2,958)
Prepaid expenses and other current assets	(1,449)	(884)
Accounts payable and other current liabilities	(3,848)	(3,691)
Income taxes receivable	5,077	1,213
Net cash provided by operating activities	34,491	32,853
Cash flows from investing activities
Capital expenditures	(4,034)	(3,860)
Proceeds from disposal of fixed assets	32
Acquisition of Gambro Water		(1,550)
Acquisition of Confirm		(855)
Acquisition of the Byrne Medical Business		(95,261)
Acquisition of SPS Business, net of cash acquired	(35,415)
Acquisition of Polyp Trap	(486)
Acquisition of Eagle Pure Water	(870)
Acquisition of Siemens Water	(8,300)
Other, net	(135)	(198)
Net cash used in investing activities	(49,208)	(101,724)
Cash flows from financing activities
Borrowings under term loan facility, net of debt issuance costs		49,647
Borrowings under revolving credit facility, net of debt issuance costs	45,000	46,941
Repayments under term loan facility	(7,500)	(7,500)
Repayments under revolving credit facility	(22,500)	(14,000)
Proceeds from exercises of stock options	1,573	1,951
Dividends paid	(1,494)	(1,258)
Excess tax benefits from stock-based compensation	1,986	1,315
Purchases of treasury stock	(1,899)	(1,502)
Net cash provided by financing activities	15,166	75,594
Effect of exchange rate changes on cash and cash equivalents	34	(106)
Increase in cash and cash equivalents	483	6,617
Cash and cash equivalents at beginning of period	30,186	18,410
Cash and cash equivalents at end of period	$ 30,669	$ 25,027